Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could essential oils tame chemo nausea? a new trial puts aromatherapy to the test

NCT ID NCT07761325

Symptom relief Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This phase III trial is testing whether adding aromatherapy—using lemon, lavender, and peppermint essential oils—to standard anti-nausea medication can better prevent nausea and vomiting in breast cancer patients receiving highly emetogenic chemotherapy. About 374 patients will be randomly assigned to receive either standard antiemetic therapy alone or standard therapy plus aromatherapy. The study will measure how many patients have no vomiting and need no rescue medication during the first five days after chemotherapy, along with quality of life and other outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Aromatherapy with lemon, lavender, and peppermint essential oils delivered via an ultrasonic diffuser, combined with standard antiemetic drugs.
What this could lead to
If effective, aromatherapy could become a simple, drug-free add-on to reduce nausea and vomiting for breast cancer patients undergoing chemotherapy, improving their quality of life.
What could go wrong
The trial is still testing the idea, and results may not show a clear benefit. Aromatherapy might not work for everyone, and any effect could be small or due to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 374 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histopathologically confirmed breast cancer (aged 18-80 years, inclusive). * Scheduled to receive or currently receiving intravenous chemotherapy, with at least 2 planned cycles. * Planned use of guideline-recommended triple antiemetic therapy (5-HT3 receptor antagonist + NK-1 receptor antagonist + dexamethasone). * ECOG performance status ≤ 2 and life expectancy ≥ 3 months. * Chemotherapy regimen classified as highly emetogenic risk according to CSCO, NCCN, or MASCC/ESMO antiemetic guidelines. * Able to understand the study procedures, voluntarily participate, and provide written informed consent. Exclusion Criteria: * History of allergy to essential oils. * History of vestibular dysfunction or intestinal obstruction. * Major cardiovascular or cerebrovascular event within the past 12 months (e.g., unstable angina, myocardial infarction, cerebral hemorrhage, cerebral infarction; asymptomatic lacunar infarction not requiring treatment is allowed). * Pregnancy, lactation, or possibility of pregnancy without willingness to use contraception. * History or current diagnosis of significant neurological or psychiatric disorders, including epilepsy or dementia. * Poor compliance anticipated, or any other condition that the investigator considers inappropriate for participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aromatherapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aromatherapy Breast cancer Chemotherapy CINV

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.